Company Description
Imunon, Inc., a clinical stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases.
The Company's lead clinical programs comprise IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development; and ThermoDox for the treatment of hepatocellular carcinoma.
It also has two platform technologies, such as TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies; and PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer.
The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022.
Imunon, Inc. was founded in 1982 and is based in Lawrenceville, New Jersey.
| Country | United States |
| Founded | 1982 |
| IPO Date | Mar 5, 1985 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Michael H. Tardugno |
Contact Details
Address: 997 Lenox Drive, Suite 100 Lawrenceville, New Jersey 08648 United States | |
| Phone | (609) 896-9100 |
| Website | imunon.com |
Stock Details
| Ticker Symbol | IMNN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0000749647 |
| ISIN Number | US15117N6022 |
| Employer ID | 52-1256615 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Michael H. Tardugno | Executive Chairman |
| Jeffrey W. Church CPA | Chief Financial Officer, Executive Vice President and Corporate Secretary |
| Dr. Khursheed Anwer M.B.A., Ph.D. | Executive Vice President and Chief Scientific Officer |
| Timothy J. Tumminello CPA | Chief Accounting Officer and Controller |
| Marianne M. Lambertson | Vice President of Communications and Investor Relations |
| Dr. Sebastien Hazard M.D. | Executive Vice President and Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 11, 2024 | 8-K | Current Report |
| Apr 10, 2024 | RW | Filing |
| Mar 28, 2024 | 10-K | Annual Report |
| Mar 28, 2024 | 8-K | Current Report |
| Mar 18, 2024 | 8-K | Current Report |
| Mar 12, 2024 | 8-K | Current Report |
| Feb 9, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Jan 18, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Dec 29, 2023 | 8-K | Current Report |
| Dec 20, 2023 | S-1 | General form for registration of securities under the Securities Act of 1933 |